EFFECTS OF ERYTHROPOIESIS-STIMULATING AGENTS ON OVERALL SURVIVAL OF IPSS LOW/INT-1 RISK TRANSFUSION INDEPENDENT MYELODYSPLASTIC SYNDROMEPATIENTS, A FISM STUDY

被引：0
|
作者：
Messa, E. [1 ]
Gioia, D. [2 ]
Masiera, E. [2 ]
Castiglione, A. [3 ]
Ceccarelli, M. [3 ]
Salvi, F. [4 ]
Danise, P. [5 ]
Sanna, A. [6 ]
Allione, B. [7 ]
Balleari, E. [8 ]
Poloni, A. [9 ]
Cametti, G. [1 ]
Ferrero, D. [7 ]
Tassara, R. [10 ]
Finelli, C. [11 ]
Bonferroni, M. [12 ]
Ciccone, G. [3 ]
Saglio, G. [13 ]
Levis, A. [2 ]
Santini, V. [6 ]
机构：
[1] ASLTO 5, Dept Internal Med, Turin, Italy
[2] Fdn Italiana Sindromi Mielodisplast Onlus, Hematol, Alessandria, Italy
[3] Azienda Osped Univ Citta Salute & Sci Torino, Piedmont Reference Ctr Canc Epidemiol & Prevent, Turin, Italy
[4] SS Antonio & Biagio Hosp, Hematol Dept, Alessandria, Italy
[5] ASL Salerno, Div Oncohematol Nocera Pagani, Salerno, Italy
[6] Azienda Osped Univ Careggi, Div Hematol, Florence, Italy
[7] Azienda Osped Univ Citta Salute & Sci Torino, Div Hematol, Turin, Italy
[8] IRCCS San Martino, Internal Med Dept, Genoa, Italy
[9] Osped Riuniti, Hematol Dept, Ancona, Italy
[10] ASL2 Savonese, Div Med & Hematol, Savona, Italy
[11] St Orsola Malpighi Univ Hosp, Inst Hematol L&A Seragnoli, Bologna, Italy
[12] Santa Croce & Carle Hosp, Div Hematol, Cuneo, Italy
[13] Mauriziano Hosp, Div Hematol, Turin, Italy
来源：
LEUKEMIA RESEARCH | 2017年 / 55卷
关键词：
D O I：
10.1016/S0145-2126(17)30206-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
93
引用
收藏
页码：S58 / S58
页数：1
相关论文
共 50 条
  • [41] Clinical benefit of luspatercept treatment (tx) in transfusion-dependent (TD), erythropoiesis-stimulating agent (ESA)-naive patients (pts) with very low-, low- or intermediate-risk myelodysplastic syndromes (MDS) in the COMMANDS trial.
    Zeidan, Amer Methqal
    Platzbecker, Uwe
    Della Porta, Matteo Giovanni
    Santini, Valeria
    Garcia-Manero, Guillermo
    Li, Jiahui
    Kreitz, Sandra
    Pozharskaya, Veronika
    Rose, Shelonitda
    Lai, Yinzhi
    Arcel, David Valc Prime
    Fenaux, Pierre
    Shortt, Jake
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes
    Zeidan, Amer M.
    Komrokji, Rami S.
    Buckstein, Rena
    Santini, Valeria
    Rose, Shelonitda
    Malini, Priya
    Lew, Glen
    Aggarwal, Dimple
    Keeperman, Karen L.
    Jiang, Huijing
    Giuseppi, Ana Carolina
    Zhang, Jennie
    Cluzeau, Thomas
    Shortt, Jake
    Platzbecker, Uwe
    BLOOD, 2023, 142
  • [43] Updated Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κb Activation
    Daher, May
    Lopez, Juliana Elisa Hidalgo
    Randhawa, Jasleen K.
    Jabbar, Kausar Jabeen
    Pemmaraju, Naveen
    Borthakur, Gautam
    Kadia, Tapan M.
    Konopleva, Marina
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    Hearn, Katherine P.
    Reyes, Steven R.
    Bueso-Ramos, Carlos E.
    Garcia-Manero, Guillermo
    BLOOD, 2016, 128 (22)
  • [44] Efficacy of Imetelstat in Achieving Red Blood Cell Transfusion Independence ( RBC-TI) across Different Risk Subgroups in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis-Stimulating Agents (ESAs) in IMerge Phase 3 Study
    Komrokji, Rami S.
    Santini, Valeria
    Fenaux, Pierre
    Savona, Michael R.
    Madanat, Yazan F.
    Berry, Tymara
    Sherman, Laurie
    Navada, Shyamala
    Feller, Faye M.
    Sun, Libo
    Xia, Qi
    Wan, Ying
    Huang, Fei
    Zeidan, Amer M.
    Platzbecker, Uwe
    BLOOD, 2023, 142
  • [45] Lenalidomide Treatment Is Not Related to AML Progression Risk but Is Associated with a Survival Benefit in RBC Transfusion-Dependent Patients with IPSS Low- or Int-1-Risk MDS with del5q: Results From a Comparative Study
    Kuendgen, Andrea
    Lauseker, Michael
    List, Alan F.
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Brandenburg, Nancy
    Backstrom, Jay
    Glasmacher, Axel
    Hasford, Joerg
    Germing, Ulrich
    BLOOD, 2011, 118 (21) : 58 - 59
  • [46] A PHASE 3 STUDY OF LENALIDOMIDE VERSUS PLACEBO IN RBC TRANSFUSION-DEPENDENT (TD) PATIENTS WITH LOWER-RISK MDS WITHOUT DEL(5Q) UNRESPONSIVE OR REFRACTORY TO ERYTHROPOIESIS-STIMULATING AGENTS (ESAS)
    Santini, V.
    Almeida, A.
    Giagounidis, A.
    Groepper, S.
    Jonasova, A.
    Vey, N.
    Mufti, G. J.
    Buckstein, R.
    Mittelman, M.
    Platzbecker, U.
    Shpilberg, O.
    Ram, R.
    del Canizo, C.
    Gattermann, N.
    Ozawa, K.
    Risueno, A.
    MacBeth, K. J.
    Zhong, J.
    Seguy, F.
    Hoenekopp, A.
    Beach, C. L.
    Fenaux, P.
    LEUKEMIA RESEARCH, 2015, 39 : S60 - S61
  • [47] Results of a Phase 1/2 Study of Lower Dose CPX-351 for Patients with Int-2 or High Risk IPSS Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia after Failure to Hypomethylating Agents
    Montalban-Bravo, Guillermo
    Jabbour, Elias
    Chien, Kelly S.
    Borthakur, Gautam
    Estrov, Zeev
    Kadia, Tapan M.
    Ravandi, Farhad
    Pemmaraju, Naveen
    Nogueras-Gonzalez, Graciela
    Schneider, Heather
    John, Rosmy
    Meyer, Meghan Anne
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Dong, Xiao Qin
    BLOOD, 2023, 142
  • [48] An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    Ades, Lionel
    Laadem, Abderrahmane
    Vo, Bond
    Prebet, Thomas
    Stamatoullas, Aspasia
    Boyd, Thomas
    Delaunay, Jacques
    Steensma, David P.
    Sekeres, Mikkael A.
    Beyne-Rauzy, Odile
    Zou, Jun
    Attie, Kenneth
    Sherman, Matthew L.
    Fenaux, Pierre
    List, Alan F.
    BLOOD, 2014, 124 (21)
  • [49] Association Of Cytogenetic Response (CyR) With RBC Transfusion-Independence (RBC-TI) and L-Free Survival In Lenalidomide (LEN)-Treated Patients (Pts) With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) With Del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    Giagounidis, Aristoteles
    List, Alan
    Schlegelberger, Brigitte
    Fenaux, Pierre
    Shiansong, Jack
    Sugrue, Mary M.
    BLOOD, 2013, 122 (21)
  • [50] Treatment with the Thrombopoietin (TPO)-Receptor Agonist Romiplostim in Thrombocytopenic Patients (Pts) with Low or Intermediate-1 (int-1) Risk Myelodysplastic Syndrome (MDS): Follow-up AML and Survival Results of a Randomized, Double-Blind, Placebo (PBO)-Controlled Study
    Kantarjian, Hagop M.
    Mufti, Ghulam J.
    Fenaux, Pierre
    Sekeres, Mikkael A.
    Szer, Jeffrey
    Platzbecker, Uwe
    Kuendgen, Andrea
    Gaidano, Gianluca
    Wiktor-Jedrzejczak, Wieslaw
    Bennett, John M.
    Meibohm, Anne
    Yang, Allen S.
    Giagounidis, Aristoteles
    BLOOD, 2012, 120 (21)
12345